Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FluLaval TF · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| FluLaval® TF | BIOLOGICAL | One IM injection. |
Inclusion Criteria: * Subjects who the investigator believes can and will comply with the requirements of the protocol * Male and female adults, 18 to 60 years of age. * Written informed consent obtained from the subject. * Satisfactory baseline medical assessment by history and physical examinatio...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
FluLaval TF is an investigational monoclonal antibody being developed by GSK plc for influenza. It is in Phase 1 clinical development and is not an approved product. The only recorded clinical study of FluLaval TF was an immunogenicity and safety trial conducted in Belgium in healthy adult volunteers aged 18 years and older.
FluLaval TF is being studied for influenza, an infectious disease. Development is at the Phase 1 stage, so the asset remains investigational and has no approved indication. The single completed trial enrolled 110 healthy adult volunteers in Belgium to assess immunogenicity and safety.
FluLaval TF is developed by GSK plc, which trades under the ticker GSK. GSK sponsored the Phase 1 study of the monoclonal antibody in influenza. No other developer or partner is associated with the asset in the available record.
FluLaval TF is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The program has not advanced beyond early clinical testing, and FluLaval TF is not an approved therapy for influenza.
FluLaval TF has been studied in one clinical trial, NCT00727428, titled Immunogenicity and Safety of GSK Biologicals' FluLaval TF. The Phase 1 study enrolled 110 healthy adult volunteers in Belgium, included both sexes, and has completed. It was an uncontrolled trial without randomization or blinding.
FluLaval TF is also written as FluLaval TF with the registered trademark symbol. The TF designation distinguishes this monoclonal antibody asset from other products sharing the FluLaval name. FluLaval TF is an investigational Phase 1 monoclonal antibody for influenza developed by GSK plc.